TP53 and acute myeloid leukemia: While TP53 mutations are widespread in solid neoplasms, they are detected in approximately 10%–15% of AML cases, with a particularly high prevalence in therapy‐related AML (t‐AML), AML with complex karyotype, and erythroid leukemia [10, 11, 12].